분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-12-22 19:18:04 , Hit : 664
 FDA Approves First Gene Therapy for Inherited Disease

https://www.genengnews.com/gen-news-highlights/fda-approves-first-gene-therapy-for-inherited-disease/81255291/?utm_medium=newsletter&utm_source=gen+daily+news+highlights&utm_content=01&utm_campaign=gen+daily+news+highlights_20171220

December 20, 2017


FDA approved Spark Therapeutics’ gene therapy Luxturna™   (voretigene neparvovec-rzyl) for treating children and adults with the rare inherited blindness disorder biallelic RPE65 mutation-associated retinal dystrophy. Approval of the one-time adeno-associated virus vector (AAV)-delivered gene therapy, which FDA Commissioner Scott Gottlieb, M.D., described in a statement as “a milestone that reinforces the potential of this breakthrough approach in treating a wide-range of challenging disease,” marks the first gene therapy approval for a genetic disease. Spark has not confirmed the cost of treatment, although some commentators are anticipating a $1 million per patient price tag. Luxturna is currently under review by the European Medicines Agency.

FDA clearance of Luxturna marks the third approval by the agency for a gene therapy, but the first for an AAV-based treatment. In August this year, the U.S. regulator cleared Novartis’ cell-based chimeric antigen receptor T-cell (CAR-T) gene therapy Kymriah™  (tisagenlecleucel) for treating refractory or relapsed B-cell acute lymphoblastic leukemia. In October, Kite Pharma’s CAR-T therapy Yescarta™ (axicabtagene ciloleucel)  was given the FDA nod for treating refractory or relapsed diffuse large B-cell lymphoma.

Administered as a subretinal injection, Luxturna uses an AAV vector to deliver a normal copy of the RPE65 gene to viable retinal cells in patients with confirmed disease. The gene therapy has been tested in two open-label Phase I studies and one open-label, controlled Phase III study, involving 41 participants aged four to 44 years at the time of treatment.

Luxturna will be administered to patients with genetically confirmed disease, by specially trained surgeons at selected centers in the U.S. Spark anticipates that the gene therapy will be available during the first quarter of 2018. The firm will manufacture Luxturna at its facility in West Philadelphia, which it says is the first manufacturing facility in the U.S. licensed for a gene therapy to treat an inherited disease.

“During the more than 12 years of innovative research with dedicated collaborators near and far, I’ve witnessed the dramatic improvement in vision in many patients who would have otherwise lost their sight,” commented Jean Bennett, M.D. Ph.D., the F.M. Kirby Professor of Ophthalmology in the Perelman School of Medicine at the University of Pennsylvania and Penn’s Scheie Eye Institute. “I believe that the success of the Luxturna clinical development program will pave the way for the development of other gene therapies that may help the millions of patients with genetic diseases who currently have limited or no treatment options.”

“This approval is a watershed milestone,” added Benjamin Yerxa, Ph.D., CEO at the Foundation Fighting Blindness (FFB), a nonprofit organization focused on research for preventing and treating blindness caused by inherited retinal diseases. “For people with an inherited retinal disease and for other patient communities, this decision may create important momentum for investigational gene therapies."

  








1067   CRISPR Efficiency Tied to Cancer-Causing Process  이성욱 2018/06/13 511
1066   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 525
1065   RNA World May Have Started Spinning with Triplet-Based Synthesis  이성욱 2018/05/21 498
1064   CRISPR’s MAGESTIC Evolution Makes Gene Editing More Precise  이성욱 2018/05/08 592
1063   CRISPR-Cas9 Improved 10,000-Fold by Synthetic Nucleotides  이성욱 2018/04/17 625
1062   Nature Methods retracts CRISPR study  이성욱 2018/04/10 744
1061   릴리 '시람자' 간암 말기 임상시험 성공  이성욱 2018/04/07 654
1060   Powerful enzyme could make CRISPR gene-editing more versatile  이성욱 2018/03/01 614
1059   Severe Toxicity Reported in High-Dose AAV Gene Therapy in Animals  이성욱 2018/02/01 768
1058   Shields Up for New Cancer Gene-Therapy Virus  이성욱 2018/02/01 673
1057   JPM서 논란 ‘유전자가위 기술’ 올해의 마일스톤은?  이성욱 2018/01/21 1170
1056   암 면역요법, 일부 환자에게만 효과 있는 이유  이성욱 2018/01/12 759
1055   [바이오토픽] CRISPR 기반 유전자치료를 방해하는 면역계  이성욱 2018/01/10 751
1054   [미국] 2017년, 유전자가위 기술을 통한 네 가지 사건들  이성욱 2018/01/10 690
1053   Using Oncolytic Viruses to Boost Response to Immune Checkpoint Inhibitors  이성욱 2018/01/05 979
1052   Alcohol Boosts Cancer Risk by Damaging Stem Cell DNA  이성욱 2018/01/05 675
1051   [바이오토픽] Science, 2017년 과학연구 총결산  이성욱 2017/12/27 1157
  FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 664
1049   Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness  이성욱 2017/12/20 536
1048   작년 바이오산업 규모 8조8775억원, 투자 13.9% 늘어  이성욱 2017/12/13 669

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN